Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECLAIM PASC colchicine platform trial
NL-OMON59195Phase 3Withdrawn
- Sponsor
- University Medical Center Utrecht
- Start
- Sep 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of colchicine in post-COVID syndrome (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: PROMIS-29 physical health summary score. Planned start Sep 2024; status: withdrawn.
02
Drugs
colchicine
03
Conditions
post-COVID syndrome
Beyond the preview
Go deeper on NL-OMON59195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59195.